The reactivity of peptidestimulated T lymphocytes obtained from patients, and, was assessed by IFN ELISPOT assay.T cells were incubated with medium alone or with the indicated tumor cell lines.Altogether, these results are, thus, consistent with those obtained by ELISPOT assays.To see whether survivinspecific T cells recognize colon cancer cells, we selected as target a panel of colorectal carcinoma CG and its HLAA engineered variant CGA, CG, CG, HCT, and SW, all HLAA positive and melanoma cell lines. The strongest tumor recognition was found for T cells from patient. IFN is one of the cytokines released by stimulated T cells.T cells of patients and were also evaluated for their capacity to release IL in response to tumor stimulation. To extend these findings, two additional colon carcinoma and two melanoma cell lines were used to stimulate survivinspecific T cells from patients and. Patients and showed also a T cellspecific response to SVV peptide. On the contrary, no activation occurred when normal epithelial cells that did not express survivin Diphenhydramine hydrochloride protein were used as source of antigens.Together with previous findings that showed the presence of survivinspecific antibodies in sera of CRC patients, our data indicate the ability of this protein to stimulate both CD and CD T cells, strongly supporting its potential role as TAA for colon carcinoma.To date very few molecules have been found to be antigenic in CRC patients, the majority of such molecules being expressed by normal mucosal cells. In the absence of the autologous tumor cells, the reactivity of survivinspecific T lymphocytes was tested using a panel of colon cancer cell lines.In fact, tumor cells are efficiently recognized by T cells and, in addition to release IFN when stimulated by colon cancer cells, survivinspecific CD T cells also released a detectable amount of IL.The mechanisms accounting for the full activation achieved by survivinspecific T cells, when stimulated by CRC cells, may include the high TCR avidityaffinity of the specific T cells in conjunction with the high level of survivin expression in tumor cells.Data are reported as pgml of IFN released evaluated by commercial ELISA.To evaluate the ability of the survivinspecific T cells to recognize the endogenous protein expressed by tumor cells, in vitro crosspresentation experiments were set up using as source of antigens cell lysates obtained from colon carcinoma. Lysate of survivintransfected CRA cell line was also added as positive control.As negative Flurbiprofen controls, lysates of primary culture of renal and ovarian normal epithelial cells were included.SURVIVIN INDUCED TUMORSPECIFIC T CELLS T cells in antitumor immunity. These data suggest a role for these CD T cells in crosspriming events occurring in vivo.However, we were unable to detect specific release of IL with our in vitro activated T cells in response to recombinant or tumorderived survivin. Studies aimed at identifying the immunogenic epitope eliciting HLA classII restricted response are currently in progress.SURVIVIN INDUCED TUMORSPECIFIC T CELLS. Click on Request Permissions which will take you to the Copyright Clearance Centers Downloaded from cancerres.aacrjournals.org on April. American Association for Cancer Research. The strong prognostic impact of the two invasion factors urokinasetype plasminogen activator, in breast cancer has recently been validated at levelI evidence.